Use of the NMDA antagonist magnesium sulfate during monitored anesthesia care for shockwave lithotripsy

Basit Öğe Kaydı
dc.contributor.authorKaymak, Çetin
dc.contributor.authorYilmaz, Erdal
dc.contributor.authorBaşar, Hülya
dc.contributor.authorÖzçakir, Sibel
dc.contributor.authorApan, Alpaslan
dc.contributor.authorBatislam, Ertan
dc.date.accessioned2020-06-25T17:44:00Z
dc.date.available2020-06-25T17:44:00Z
dc.date.issued2007
dc.descriptionBatislam, Ertan/0000-0002-7493-4573
dc.description.abstractPurpose: To assess whether intravenous magnesium sulfate infusion affects analgesic requirements during monitored anesthesia care (MAC) for shockwave lithotripsy (SWL). Patients and Methods: Fifty patients in ASA class I or II undergoing SWL with MAC were randomized into two groups. Induction of MAC was produced by bolus doses of midazolam 0.03 mg/kg(-1) and fentanyl 0.5 mu g/kg(-1) followed by intravenous infusion of midazolam 0.015 to 0.06 mg/kg(-1)/hr(-1) with fentanyl supplementation 0.2 mu g/kg(-1). In addition, group I patients received magnesium sulfate 30 mg/kg(-1) intravenously as a bolus dose followed by a continuous infusion of 10 mg/kg(-1) /hr(-1) beginning 15 minutes before induction of sedation. The midazolam infusion rate and additional fentanyl doses were adjusted by verbal analog scale (VAS) measurements, observer assessment sedation score (OAA/S), and achieving a target bispectral index (BIS) in a range of 70 to 90. At the end of SWL, the total midazolam and total fentanyl consumptions were recorded, and the serum magnesium concentration was measured. Results: Magnesium caused significant decreases in the total consumption of midazolam (P = 0.001) and fentanyl (P = 0.001). The VAS values at the 15th, 20th, and 25th minute in group I were significantly lower than in group II. In group I, hemodynamic and arterial oxygen parameters were better than in group II. Conclusion: A magnesium bolus and infusion can be utilized to reduce analgesic requirements under MAC during SWL.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1089/end.2006.0195
dc.identifier.endpage150en_US
dc.identifier.issn0892-7790
dc.identifier.issn1557-900X
dc.identifier.issue2en_US
dc.identifier.pmid17338610
dc.identifier.scopus2-s2.0-33947406415
dc.identifier.scopusqualityQ1
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org10.1089/end.2006.0195
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3977
dc.identifier.volume21en_US
dc.identifier.wosWOS:000244914800038
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofJournal Of Endourology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleUse of the NMDA antagonist magnesium sulfate during monitored anesthesia care for shockwave lithotripsyen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Use of the NMDA antagonist magnesium sulfate during monitored anesthesia care for shockwave lithotripsy.pdf
Boyut:
4.4 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu